Drug Information

Drug General Information
Drug ID
D06TGE
Former ID
DCL000327
Drug Name
Taranabant
Synonyms
Taranabant [USAN]; MK 0364; MK0364; MK-0364; MK-0634; Taranabant (INN/USAN); L]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide; N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropy; N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide; N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide; N-((1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
Drug Type
Small molecular drug
Indication Obesity [ICD9: 278; ICD10:E66] Discontinued in Phase 3 [537068]
Company
Merck
Structure
Download
2D MOL

3D MOL
Formula
C27H25ClF3N3O2
Canonical SMILES
CC(C(CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3<br />=NC=C(C=C3)C(F)(F)F
InChI
1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1
InChIKey
QLYKJCMUNUWAGO-GAJHUEQPSA-N
CAS Number
CAS 701977-09-5
PubChem Compound ID
11226090
PubChem Substance ID
16309390, 23408060, 42305700, 50076997, 50086932, 57309658, 80708182, 96025692, 103504206, 104080908, 109692760, 126671461, 134338981, 135207455, 135343827, 137010390, 140904404, 152258058, 160646896, 172658609, 172919623, 184816678, 198978240, 198991966, 223592739, 223679364, 226644847, 241139588, 249125771, 252160245, 252215860, 252481191
Target and Pathway
Target(s) Cannabinoid receptor 1 Target Info Antagonist [537149]
KEGG Pathway Rap1 signaling pathway
Neuroactive ligand-receptor interaction
Retrograde endocannabinoid signaling
PANTHER Pathway Endogenous cannabinoid signaling
Pathway Interaction Database N-cadherin signaling events
Reactome Class A/1 (Rhodopsin-like receptors)
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Small Ligand GPCRs
BDNF signaling pathway
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 537068Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
Ref 537149Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.